04:35 AM EST, 11/24/2025 (MT Newswires) -- Merck ( MRK ) said late Friday that shareholders should not participate in the unsolicited mini-tender offer launched by Tutanota at $65 per share, which is well below recent market prices.

The company said Tutanota plans to buy up to 1 million of its shares, at a price more than 31% below last Thursday's closing level.

The drugmaker added that shareholders should also refrain from participating due to the numerous conditions attached to the offer and Merck's ( MRK ) lack of any affiliation with Tutanota.

Investors who have already tendered their shares may withdraw them before the offer expires on Dec. 15.